Patents by Inventor Gunnar E. Jagdmann

Gunnar E. Jagdmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arginase inhibitors as therapeutics
    Patent number: 11389464
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 19, 2022
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20210261573
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
  • Compositions and methods for inhibiting arginase activity
    Patent number: 11021495
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20200339607
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 29, 2020
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
  • Arginase Inhibitors as Therapeutics
    Publication number: 20200246362
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 6, 2020
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Arginase inhibitors as therapeutics
    Patent number: 10603330
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 31, 2020
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10597411
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20190330244
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 31, 2019
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjær PETERSEN
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10287303
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 14, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20190054101
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Arginase inhibitors as therapeutics
    Patent number: 10098902
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 16, 2018
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180222926
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 9, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Jr, Lene Raunkjaer PETERSEN, Francesco PARLATI, Matthew I. GROSS
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20170000808
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 5, 2017
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Arginase inhibitors as therapeutics
    Patent number: 9440995
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 13, 2016
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20150191492
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 9, 2015
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • N-cyanoamidine derivatives as anti-influenza agents
    Patent number: 5519037
    Abstract: Antiinfluenza A activity was found in compounds of the formula: ##STR1## wherein X is ##STR2## where one of R.sup.1 and R.sup.2 is H and the other is phenylamino and Z is --SCH.sub.3 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: May 21, 1996
    Assignee: American Home Products Corporation
    Inventors: Kuo-Hom L. Hsu, Daniel M. Teller, Alan R. Davis, Michael D. Lubeck, Harry R. Munson, Jr., Gunnar E. Jagdmann, Ibrahim M. Uwaydah
  • N-cyanoamidine derivatives as anti-influenza agents
    Patent number: 5475012
    Abstract: Antiinfluenza A activity was found in compounds of the formula: ##STR1## wherein: X is 2-phenylethyl, 2-furanylmethyl, or ##STR2## where one of R.sup.1 and R.sup.2 is H and the other is phenylamino; Z is --SCH.sub.3 when X is ##STR3## or ##STR4## when X is 2-phenylethyl or 2-furanylmethyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: December 12, 1995
    Assignee: American Home Products Corporation
    Inventors: Kuo-Hom L. Hsu, Daniel M. Teller, Alan R. Davis, Michael D. Lubeck, Harry R. Munson, Jr., Gunnar E. Jagdmann, Ibrahim M. Uwaydah
  • N-cyanoamidine derivatives as anti-influenza agents
    Patent number: 5380734
    Abstract: Antiinfluenza A activity was found in compounds of the formula: ##STR1## wherein: X is 2-phenylethyl, 2-furanylmethyl, or ##STR2## where one of R.sup.1 and R.sup.2 is H and the other is phenylamino; Z is --SCH.sub.3 when X is ##STR3## when X is 2-phenylethyl or 2-furanylmethyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 15, 1993
    Date of Patent: January 10, 1995
    Assignee: American Home Products Corporation
    Inventors: Kuo-Hom L. Hsu, Daniel M. Teller, Alan R. Davis, Michael D. Lubeck, Harry R. Munson, Jr., Gunnar E. Jagdmann, Ibrahim M. Uwaydah
  • [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
    Patent number: 5273972
    Abstract: This invention provides novel 2-substituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals.Illustrative of an invention compound is 5-chloro-2-methoxy-4-(methylamino)-N-[2-(1-piperidinylmethyl)-1-azabicyclo [2.2.2]oct-3-yl]benzamide: ##STR1## or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: December 28, 1993
    Assignee: A. H. Robins Company, Incorporated
    Inventors: Gunnar E. Jagdmann, Harry R. Munson, Jr.
  • Carbocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
    Patent number: 5244907
    Abstract: Novel 1-azabicyclo[3.2.1]octan-5-ylmethyl and 1-azabicyclo[3.3.1]nonan-5-ylmethyl amines and alcohols are coupled with aryl carboxylic acids to obtain compounds having the formula: ##STR1## wherein X is --O-- or --NH-- and n is 1 or 2 which are useful in increasing gastric motility, in preventing emesis and emesis caused by anticancer treatments, anxiety, certain arrhythmias, and disorders caused by serotonin imbalances.
    Type: Grant
    Filed: November 17, 1992
    Date of Patent: September 14, 1993
    Assignee: A. H. Robins Company, Incorporated
    Inventors: Harry R. Munson, Jr., Gunnar E. Jagdmann